ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Phase 3positiveENHERTUPositive

AI Analysis

Summary

ENHERTU demonstrated a median progression-free survival of 14.3 months in the DESTINY-Lung04 Phase III trial as first-line therapy for HER2-mutant advanced non-small cell lung cancer. This positive Phase 3 data supports the therapeutic potential of the drug in this indication.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

DESTINY-Lung04 Phase III trial demonstrated median progression-free survival of 14.3 months as 1st-line therapy in HER2-mutant advanced non-small cell lung cancer

Importance:7/10

Sentiment:

0.75

Phase_3_DataOncologyLung_CancerHER2_MutationENHERTUFirst_Line_Therapy

Related Companies

$DSKYF

Read the original article

Published by yahoo_finance on September 14, 2026 1:55 AM

Read Original